Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Cancer Treatment Reviews · 2023-06 · 117 · 102569
DOI: 10.1016/j.ctrv.2023.102569 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023-06. Verfasst von Chiara Corti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncolog…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 81 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato - Oncology (DIPO), University of Milan, Milan, Italy.
- Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy; Laster and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
- Department of Medical Oncology, Ospedale San Raffaele, IRCCS, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
- "Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Azienda USL Toscana Centro, Prato, Ita…
- Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, PLLC, Nashville, TN, USA.
- Breast Oncology Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Division of Molecular and Cellular Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Center for Functional Ca…
Zitieren
APA
Corti, C., De Angelis, C., Bianchini, G., Malorni, L., Giuliano, M., Hamilton, E., Jeselsohn, R., Jhaveri, K., Curigliano, G., & Criscitiello, C. (2023). Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?. Cancer Treatment Reviews, 117, 102569. https://doi.org/10.1016/j.ctrv.2023.102569
Vancouver
Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, et al. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?. Cancer Treatment Reviews. 2023;117:102569. doi:10.1016/j.ctrv.2023.102569
BibTeX
@article{Corti2023,
author = {Corti, Chiara and De Angelis, Carmine and Bianchini, Giampaolo and Malorni, Luca and Giuliano, Mario and Hamilton, Erika and Jeselsohn, Rinath and Jhaveri, Komal and Curigliano, Giuseppe and Criscitiello, Carmen},
title = {Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?},
journal = {Cancer Treatment Reviews},
year = {2023},
volume = {117},
pages = {102569},
doi = {10.1016/j.ctrv.2023.102569}
}
EUVIMED